Research programme: anti CD44v6 CAR transduced T-cells - MolMed/San Raffaele HospitalAlternative Names: CAR-CD44v6 immune gene therapy - MolMed; Chimeric antigen receptor CD44v6 immune gene therapy - MolMed
Latest Information Update: 19 May 2015
At a glance
- Originator Scientific Institute San Raffaele
- Class CAR-T cell therapies; Gene therapies
- Mechanism of Action CD44 antigen inhibitors; Cytotoxic T lymphocyte stimulants; Gene transference; T lymphocyte replacements
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- Preclinical Haematological malignancies; Solid tumours